These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 26812877)

  • 21. The progesterone derivative dydrogesterone abrogates murine stress-triggered abortion by inducing a Th2 biased local immune response.
    Joachim R; Zenclussen AC; Polgar B; Douglas AJ; Fest S; Knackstedt M; Klapp BF; Arck PC
    Steroids; 2003 Nov; 68(10-13):931-40. PubMed ID: 14667986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of sub-endometrial blood flow parameters following dydrogesterone and micronized vaginal progesterone administration in women with idiopathic recurrent miscarriage: a pilot study.
    Ghosh S; Chattopadhyay R; Goswami S; Chaudhury K; Chakravarty B; Ganesh A
    J Obstet Gynaecol Res; 2014 Jul; 40(7):1871-6. PubMed ID: 25056464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of different progestogens on sleep in postmenopausal women: a randomized trial.
    Leeangkoonsathian E; Pantasri T; Chaovisitseree S; Morakot N
    Gynecol Endocrinol; 2017 Dec; 33(12):933-936. PubMed ID: 28609128
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of dydrogesterone on the vascular system.
    Seeger H; Mueck AO
    Gynecol Endocrinol; 2007 Oct; 23 Suppl 1():2-8. PubMed ID: 17943533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Dydrogesterone (Duphaston) in the prevention of risk of ultrasound guided amniocentesis].
    Korczyński J
    Ginekol Pol; 2000 Aug; 71(8):709-13. PubMed ID: 11082907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A systematic review of dydrogesterone for the treatment of threatened miscarriage.
    Carp H
    Gynecol Endocrinol; 2012 Dec; 28(12):983-90. PubMed ID: 22794306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dydrogesterone: pharmacological profile and mechanism of action as luteal phase support in assisted reproduction.
    Griesinger G; Tournaye H; Macklon N; Petraglia F; Arck P; Blockeel C; van Amsterdam P; Pexman-Fieth C; Fauser BC
    Reprod Biomed Online; 2019 Feb; 38(2):249-259. PubMed ID: 30595525
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful prevention of preeclampsia in a high-risk pregnancy using progestogen dydrogesterone: a clinical case.
    Tskhay VB; Kovtun NM; Schindler AE
    Horm Mol Biol Clin Investig; 2016 Sep; 27(3):85-8. PubMed ID: 27383893
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dydrogesterone support following assisted reproductive technique (ART) reduces the risk of pre-eclampsia.
    Ali AB; Ahmad MF; Kwang NB; Shan LP; Shafie NM; Omar MH
    Horm Mol Biol Clin Investig; 2016 Sep; 27(3):93-6. PubMed ID: 26910749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of dydrogesterone supplementation on serum cytokine profile in women with threatened abortion.
    Kalinka J; Radwan M
    Am J Reprod Immunol; 2006 Feb; 55(2):115-21. PubMed ID: 16433830
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Impact of Oral Intake of Dydrogesterone on Fetal Heart Development During Early Pregnancy.
    Zaqout M; Aslem E; Abuqamar M; Abughazza O; Panzer J; De Wolf D
    Pediatr Cardiol; 2015 Oct; 36(7):1483-8. PubMed ID: 25972284
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of dydrogesterone as a progestogen for oral contraception.
    Coelingh Bennink HJ; Boerrigter PJ
    Steroids; 2003 Nov; 68(10-13):927-9. PubMed ID: 14667985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modulation of cytokine production by dydrogesterone in lymphocytes from women with recurrent miscarriage.
    Raghupathy R; Al Mutawa E; Makhseed M; Azizieh F; Szekeres-Bartho J
    BJOG; 2005 Aug; 112(8):1096-101. PubMed ID: 16045524
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The randomised controlled trial of micronised progesterone and dydrogesterone (TRoMaD) for threatened miscarriage.
    Siew JYS; Allen JC; Hui CYY; Ku CW; Malhotra R; Østbye T; Tan TC
    Eur J Obstet Gynecol Reprod Biol; 2018 Sep; 228():319-324. PubMed ID: 30077119
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dydrogesterone indications beyond menopausal hormone therapy: an evidence review and woman's journey.
    Stute P
    Gynecol Endocrinol; 2021 Aug; 37(8):683-688. PubMed ID: 33866898
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dydrogesterone supplementation in women with threatened preterm delivery--the impact on cytokine profile, hormone profile, and progesterone-induced blocking factor.
    Hudić I; Szekeres-Bartho J; Fatušić Z; Stray-Pedersen B; Dizdarević-Hudić L; Latifagić A; Hotić N; Kamerić L; Mandžić A
    J Reprod Immunol; 2011 Dec; 92(1-2):103-7. PubMed ID: 22032897
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The impact of dydrogesterone supplementation on hormonal profile and progesterone-induced blocking factor concentrations in women with threatened abortion.
    Kalinka J; Szekeres-Bartho J
    Am J Reprod Immunol; 2005 Apr; 53(4):166-71. PubMed ID: 15760377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world pharmacological treatment patterns of patients with threatened miscarriage in China from 2014 to 2020: A cross-sectional analysis.
    Pang YY; Ma CL
    J Clin Pharm Ther; 2022 Feb; 47(2):228-236. PubMed ID: 34704273
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dydrogesterone--a unique progestogen.
    Schindler AE
    Maturitas; 2009 Dec; 65 Suppl 1():S1. PubMed ID: 19781875
    [No Abstract]   [Full Text] [Related]  

  • 40. Dydrogesterone treatment for menstrual-cycle regularization in routine clinical practice: a multicenter observational study.
    Podzolkova N; Tatarchuk T; Doshchanova A; Eshimbetova G; Pexman-Fieth C
    Gynecol Endocrinol; 2016; 32(3):246-9. PubMed ID: 26613278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.